Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (NCT05702229)

🧪 Interventions in This Study

• Rilvegostomig (DRUG)
• Volrustomig (DRUG)
• FOLFOX (DRUG)
• XELOX (DRUG)
• AZD0901 (DRUG)
• 5-Fluorouracil (DRUG)
• Capecitabine (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (44 Sites)

Showing the first 25 of 44 sites.

• Research Site — Los Angeles, California
• Research Site — Los Angeles, California
• Research Site — Baton Rouge, Louisiana
• Research Site — Grand Rapids, Michigan
• Research Site — New Hyde Park, New York
• Research Site — New York, New York
• Research Site — New York, New York
• Research Site — New York, New York
• Research Site — Shirley, New York
• Research Site — The Bronx, New York
• Research Site — Pittsburgh, Pennsylvania
• Research Site — Beijing,
• Research Site — Hangzhou,
• Research Site — Hangzhou,
• Research Site — Harbin,
• Research Site — Hefei,
• Research Site — Kunming,
• Research Site — Wuhan,
• Research Site — Yinchuan,
• Research Site — Zhengzhou,
• Research Site — Chūōku,
• Research Site — Kashiwa,
• Research Site — Sunto-gun,
• Research Site — Seoul,
• Research Site — Seoul,

📞 Contact the Study Coordinator

Phone: (877) 240-9479

Email: information.center@astrazeneca.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Gastric Cancer

• A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors — Scottsdale, Arizona
• Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer — Los Angeles, California
• Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) — Baltimore, Maryland
• Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer — Baltimore, Maryland
• Study for AZD4360 in Participants With Advanced Solid Tumours — Santa Monica, California
• Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma — Tampa, Florida

Explore by condition: All Gastric Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.